PARP inhibitors in gastric cancer: beacon of hope
Abstract Defects in the DNA damage response (DDR) can lead to genome instability, producing mutations or aberrations that promote the development and progression of cancer. But it also confers such cells vulnerable to cell death when they inhibit DNA damage repair. Poly (ADP-ribose) polymerase (PARP...
Main Authors: | Yali Wang, Kun Zheng, Yongbiao Huang, Hua Xiong, Jinfang Su, Rui Chen, Yanmei Zou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13046-021-02005-6 |
Similar Items
-
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
by: Abdullah Alhusaini, et al.
Published: (2021-08-01) -
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
by: Elizabeth K. Lee, et al.
Published: (2020-07-01) -
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
by: Maddison Rose, et al.
Published: (2020-09-01) -
PARP Inhibitors in Prostate and Urothelial Cancers
by: Rohan Garje, et al.
Published: (2020-02-01) -
A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy
by: Shah Ashish P., et al.
Published: (2018-03-01)